Recordati Quote - REC

Professional-Grade Tools, for Individual Investors.

Premium

Current Price

50.20

Bid

50.20

Ask

50.25

Volume

59,236

50.10 Day's Range 50.45

43.88 52 Week Range 54.80

Market Cap

10.309B

Previous Close

50.45

Open

50.40

Last Trade

109

50.2

Last Trade Time

06:04:27

Financial Volume

VWAP

Average Volume (3m)

249,127

Shares Outstanding

205,358,104

Dividend Yield

2.45%

PE Ratio

27.57

Earnings Per Share (EPS)

1.9

Revenue

2.07B

Net Profit

389.21M

Sector

Pharmaceutical Preparations

Industry

Pharmaceutical Preparations

Website

www.recordati.it

Headquarters

Milan, Lombardy, Ita

Founded

1926

Recordati SpA is listed in the Pharmaceutical Preparations sector of the Italian Stock Exchange with ticker REC. The last closing price for Recordati was 50.45 €. Over the last year, Recordati shares have traded in a share price range of 43.88 € to 54.80 €.

Recordati currently has 205,358,104 shares outstanding. The market capitalization of Recordati is 10.36 € billion. Recordati has a price to earnings ratio (PE ratio) of 27.57.

RECORDATI: CONTINUED DOUBLE-DIGIT GROWTH IN THE FIRST NINE MONTHS OF 2024 - REVENUE +12.0%, EBITDA(1) +11.8%, ADJUSTED NET INCOME(2) +9.5%

RECORDATI: CONTINUED DOUBLE-DIGIT GROWTH IN THE FIRST NINE MONTHS OF 2024 - REVENUE +12.0%, EBITDA(1) +11.8%, ADJUSTED NET INCOME(2) +9.5% Consolidated net revenue of € 1,743.1 million in the...

RECORDATI ANNOUNCES AGREEMENT TO ACQUIRE THE GLOBAL RIGHTS TO ENJAYMO®, STRENGTHENING ITS RARE DISEASES FRANCHISE

RECORDATI ANNOUNCES AGREEMENT TO ACQUIRE THE GLOBAL RIGHTS TO ENJAYMO®, STRENGTHENING ITS RARE DISEASES FRANCHISE Milan, 4th October 2024 – Recordati today announces an agreement with Sanofi...

Recordati Rare Diseases annonce la publication dans The Journal of Clinical Endocrinology & Metabolism des résultats de l’étude de Phase III LINC 4 confirmant l'efficacité et la tolérance d’Isturisa® (osilodrostat)...

L’étude LINC 4 a démontré la supériorité d’Isturisa® (osilodrostat) comparé au placebo pour normaliser le cortisol au cours de la phase de 12 semaines en double aveugle, randomisée de l’étude (77...

RECORDATI: I RISULTATI POSITIVI DELLO STUDIO DI FASE III LINC-4 PRESENTATI AL CONGRESSO ANNUALE DELLA ENDOCRINE SOCIETY RICON...

RECORDATI: I RISULTATI POSITIVI DELLO STUDIO DI FASE III LINC-4 PRESENTATI AL CONGRESSO ANNUALE DELLA ENDOCRINE SOCIETY RICONFERMANO L’EFFICACIA E LA SICUREZZA DI ISTURISA® (OSILODROSTAT) PER...

Recordati Rare Diseases: Positive Results From the Phase III LINC 4 Study Presented Today at the Endocrine Society’s Annual...

Statistically significant results from the pivotal Phase III LINC 4 study demonstrate that Isturisa® (osilodrostat) provides rapid and sustained normalisation of mean urinary free cortisol levels...

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	-1.7	-3.27552986513	51.9	52.05	49.48	274080	50.50065145	DE
4	-3.45	-6.43056849953	53.65	54.45	48.58	268850	51.71780314	DE
12	-2.35	-4.47193149382	52.55	54.8	48.58	249127	51.83904267	DE
26	0	0	50.2	54.8	47.28	241758	50.67472884	DE
52	5.67	12.7329889962	44.53	54.8	43.88	233555	50.25214384	DE
156	-6.02	-10.7079331199	56.22	56.96	34.52	236167	45.82020012	DE
260	12.24	32.2444678609	37.96	57.9	28.26	283137	44.68793713	DE

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
WGML25GM Leather spa	0.013 € (30.00%)	3k
WSAC25Saccheria Flli Franceschetti SpA	0.032 € (28.00%)	1,000
1SNOWSnowflake Inc	149.12 € (21.35%)	2.1k
WSGC28SG Company SpA	0.0259 € (16.14%)	80k
WIVN26iVision Tech SpA	0.30 € (15.38%)	20k
1VARVarta AG	2.05 € (-13.14%)	15.36k
1DTRHDaimler Truck Holding AG	36.77 € (-11.72%)	3
ECNLAAAquafil SpA	0.0365 € (-10.98%)	133.55k
BIEBioera SPA	0.034 € (-10.53%)	139k
1ROKURoku Inc	63.41 € (-10.31%)	40
TITTelecom Italia SpA	0.2309 € (-1.24%)	61.23M
ISPIntesa Sanpaolo Spa	3.685 € (-0.31%)	28.93M
SPMSaipem Spa	2.351 € (1.03%)	13.04M
ENELEnel Spa	6.599 € (0.53%)	7.69M
TITRTelecom Italia	0.2754 € (-1.50%)	7.31M